Zilebesiran, a ribonucleic acid interference agent targeting angiotensinogen, proves a promising approach in hypertension.

Competing Interests: Conflict of interest: Professor Webb’s employer, the University of Edinburgh, has been paid by Alnylam for his contributions to the zilebesiran programme in hypertension. He has undertaken recent consultancy roles with Idorsia, Janssen, and Silence pharmaceuticals in the field of cardiovascular research.